iCAD (NASDAQ:ICAD – Get Free Report) was downgraded by stock analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued to investors on Wednesday.
iCAD Stock Up 2.9 %
iCAD stock traded up $0.04 during trading hours on Wednesday, hitting $1.40. The stock had a trading volume of 861,372 shares, compared to its average volume of 168,031. The stock’s 50-day moving average price is $1.34 and its 200-day moving average price is $1.49. The stock has a market capitalization of $37.16 million, a P/E ratio of -11.67 and a beta of 1.50. iCAD has a 12-month low of $1.18 and a 12-month high of $2.65.
iCAD (NASDAQ:ICAD – Get Free Report) last announced its quarterly earnings data on Tuesday, May 14th. The technology company reported ($0.05) earnings per share for the quarter. The firm had revenue of $4.95 million during the quarter. iCAD had a negative return on equity of 14.00% and a negative net margin of 15.20%.
Hedge Funds Weigh In On iCAD
iCAD Company Profile
iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.
Read More
- Five stocks we like better than iCAD
- 3 Fintech Stocks With Good 2021 Prospects
- Brinker International’s Price Dip is an Appetizing Entry Point
- Best Stocks Under $10.00
- 3 Stocks That Could Beat the September Blues
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Canopy Growth Stock: Can It Sustain Recent Gains?
Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with MarketBeat.com's FREE daily email newsletter.